What AI says about Andembry

ANDEMBRY is a prescription monoclonal antibody (garadacimab-gxii) injection used to prevent hereditary angioedema (HAE) attacks in people 12 years and older, by inhibiting FXIIa at the top of the HAE pathway. It is given as a subcutaneous self‑injection once monthly, delivered in ≤15 seconds with an autoinjector. Clinical data show substantial, durable reductions in monthly HAE attack rates, and the therapy is manufactured by CSL Behring and supported by ANDEMBRY Connect and related resources.